NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
New relationship aims to combine access to anonymised patient data with clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.
Oxford, UK; 5th July 2018: Drayson Health Limited (the “Company”), a British healthcare technology company focused on accelerating medical research and improving patient care, announces today that it has signed a Memorandum of Understanding (MoU) with South Warwickshire NHS Foundation Trust.
The MoU builds on an existing relationship with South Warwickshire NHS Foundation Trust formed in September 2017 for the Trust to utilise Drayson Health’s SEND™ digital charting system, invented by clinicians in Oxford*, for monitoring and collating vital signs observations. SEND™ is now fully deployed in South Warwickshire NHS Foundation Trust and in everyday clinical use, for the primary purpose of replacing paper charting at the bedside, helping nurses to deliver safer, more efficient patient care in the hospital. The MoU allows clinicians and AI experts to develop digital health products that will deliver benefits to patients using anonymised datasets from the South Warwickshire NHS Foundation Trust.
South Warwickshire NHS Foundation Trust now joins Oxford University Hospitals NHS Foundation Trust and the University of Oxford which signed a similar agreement with Drayson Health in 2017.
In line with Drayson Health’s business model, research using the data is undertaken to the highest standards of transparency and governance whereby all appropriate controls and safeguards are put in place to protect patients’ personal data in accordance with the NHS’ Caldicott Principles on information governance. The Company is committed to maintaining the trust and confidence of clinicians, patients and the public. The Company is committed to ensuring there is no compromise in ensuring that this data is properly consented and treated with the utmost care and security.
In addition, Drayson Health notes its intention to change its name to Sensyne Health and in light of its commitment to high standards of governance and transparency plans to float on the London Stock Exchange in the near future.
GLEN BURLEY, CEO, SOUTH WARWICKSHIRE NHS FOUNDATION TRUST, COMMENTED:
“We are excited to continue working with Drayson Health. The SEND system offers lots of benefits to patients and clinicians. It was developed by clinicians for clinicians and we are seeing dramatic improvements in clinical efficiency and safety. We have data that was previously captured on paper now digitised, enabling greater support to clinical care delivery to our patients and in tandem, the potential to support future medical discoveries.”
PAUL, LORD DRAYSON, CEO OF DRAYSON HEALTH, COMMENTED:
“The NHS has the best health data set in the world. To have access to it is a privilege, and we owe it to the British public to utilise it in the right way - responsibly and for the ultimate benefit of patients. We have the opportunity to make significant improvements to patient care, reduce costs for the NHS and generate a financial return for our NHS partners which may be re-invested for the benefit of local patients.”
For more information please contact:
Notes for editors:
ABOUT DRAYSON HEALTH
Drayson Health, soon to be Sensyne Health, is a British healthcare technology company using real world data powered by artificial intelligence to develop regulatory approved digital therapeutic products and hospital systems for clinical care. The Company works in partnership with the University of Oxford and Oxford University Hospitals NHS Foundation Trust for whom it is the exclusive partner for the commercialisation of certain digital health innovations designed to improve patient outcomes and efficiency within the NHS and beyond. Drayson Health has developed three clinically validated software applications (SEND™, GDm-Health™ and Edge™) designed to connect patients, clinicians and researchers, generate large databases of phenotypic data, and enable discovery research.
Drayson Health, is based in the Big Data Institute (BDI) at the University of Oxford's Old Road Campus. Lord Drayson leads the Drayson Health team, which combines experience in artificial intelligence, digital health and life sciences. The team is advised by a distinguished Scientific Advisory Board, chaired by Professor Sir John Bell.
For more information, please visit: www.draysonhealth.com
SEND™ is Drayson Health’s digital charting system for monitoring and collating vital-signs observations in hospital. *The University of Oxford and Oxford University Hospitals NHS Foundation Trust developed and trialled SEND in the Oxford Biomedical Research Centre (BRC) funded by the National Institute for Health Research (NIHR). SEND is in everyday clinical use at South Warwickhire NHS Foundation Trust and across all 4 hospitals within the Oxford University Hospitals NHS Foundation Trust for the primary purpose of replacing paper charting at the bedside and enabling nurses to deliver safer, more efficient patient care in the hospital and earlier detection of deteriorating patients through the digitisation of Early Warning Scores).
ABOUT SOUTH WARWICKSHIRE NHS FOUNDATION TRUST
South Warwickshire NHS Foundation Trust (SWFT) provides the hospital services to South Warwickshire from four hospitals:
- Warwick Hospital
- Leamington Spa Hospital
- Stratford Hospital
- Ellen Badger Hospital
We also deliver out-of-hospital community services to the whole of Warwickshire serving a population of more than half a million from various clinics.
WHAT IS ‘CLINICAL AI’?
Clinical AI is a highly specialised field of AI which uses machine learning algorithms, including deep learning in tandem with human clinical expertise and big datasets with which to train the algorithms. Clinical AI is particularly concerned with the analysis of data acquired during routine clinical care of patients, in order to derive clinically-useful results such as to improve patient outcomes and to discover new insights about the use of pharmaceutical compounds to treat patients.
This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.
These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.